Proteinuria Kidney Disease Clinical Trials

A clinical research study evaluating investigational oral treatments for children and adults with APOL1-mediated proteinuric kidney disease.

Research Study for Proteinuria Kidney Disease

Explore clinical research studies for children and adults with APOL1-mediated proteinuric kidney disease. Investigational oral treatments are being evaluated for safety and how they may support kidney health over time.

Age
18 Years to 67 Years

Gender
Male & Female

Condition
APOL1 Mediated Proteinuric Kidney Disease

Location
Florida

Questions or Interested in a Trial?

This field is for validation purposes and should be left unchanged.

Understanding APOL1-Mediated Proteinuric Kidney Disease

APOL1-mediated proteinuric kidney disease is linked to inherited APOL1 gene variants that can increase the risk of kidney damage. One common sign is excess protein in the urine, which may indicate stress or injury to the kidneys.

Frequently Asked Questions

Find answers to common questions about eligibility, participation, and what to expect.

These clinical studies are evaluating the safety, tolerability, and potential effectiveness of investigational treatments for APOL1-mediated proteinuric kidney disease. Researchers are also studying how these treatments may help reduce protein in the urine and support kidney health over time.

Adults aged 18–67, and children or adults aged 10–65, may qualify depending on the available study. Eligibility is based on age, APOL1 gene variant status, kidney health, and medical history. Some studies may be open to participants with Type 2 diabetes, while others are not — our team can help determine which study may be the right fit. Contact us for a full eligibility review.u0

Participation may include screening visits, taking study tablets, attending regular check-ins, completing lab and urine tests, and follow-up visits. Study schedules may vary depending on which trial is the best fit.

Yes. All clinical studies involve possible risks. These will be explained during the informed consent process, and participant safety is carefully monitored throughout the study.

There is no cost for study-related care. Compensation may be available for eligible participants, depending on the study.